Seminars in Oncology
Volume 33, Issue 2 , Pages 186-194, April 2006

Risk Stratification in Chronic Lymphocytic Leukemia

Department of Internal Medicine III, University of Ulm, Ulm, Germany.

Chronic lymphocytic leukemia (CLL) follows an extremely variable clinical course with survival ranging from months to decades. Available treatments can often induce remissions, but eventually all patients relapse. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in patients with CLL. Genomic aberrations, the mutational profile of IgVH genes and its surrogate marker ZAP-70 expression, and serum markers like B2 -microglobuline (β2-MG) and thymidine kinase (TK) provide prognostic information for individual patients independently of clinical disease characteristics. These molecular markers are about to enter the stage of risk stratification for individual patients in clinical trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Wilhelm Sander-Stiftung (2003.086.1, 2001.004.2), Deutsche Krebshilfe (106116, 70-3173-Tr 3 B4), Fresenius Stiftung (CLL4VH), Amgen, Roche, and Schering.

PII: S0093-7754(06)00026-1

doi:10.1053/j.seminoncol.2006.01.017

Seminars in Oncology
Volume 33, Issue 2 , Pages 186-194, April 2006

Article Tools

* Image Usage & Resolution